Pyxis Oncology
PYXS

$3.88

0.26%

Market Cap: 228M

About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Employees: 51

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

517% more capital invested

Capital invested by funds: $15.8M [Q4 2023] → $97.7M (+$81.8M) [Q1 2024]

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

167% more call options, than puts

Call options by funds: $543K | Put options by funds: $203K

37% more funds holding

Funds holding: 51 [Q4 2023] → 70 (+19) [Q1 2024]

19.6% more ownership

Funds ownership: 19.85% [Q4 2023] → 39.44% (+19.6%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$7

80%

upside

Avg. target

$7.67

98%

upside

High target

$10

158%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth	80%upside $7	Buy Reiterated	16 May 2024
Jefferies Farzin Haque	158%upside $10	Buy Assumed	7 May 2024
HC Wainwright & Co. Swayampakula Ramakanth	80%upside $7	Buy Reiterated	10 Apr 2024
RBC Capital Leonid Timashev	80%upside $7	Outperform Reiterated	22 Mar 2024
HC Wainwright & Co. Swayampakula Ramakanth	80%upside $7	Buy Maintained	22 Mar 2024

See Analyst Rankings

Financial journalist opinion

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Zacks Investment Research

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings.

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Zacks Investment Research

Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology's common stock to a newly hired employee. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of March 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 Biotech Stocks to Buy on the Dip: March 2024

One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.

3 Biotech Stocks to Buy on the Dip: March 2024

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu ® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million. As part of Pyxis Oncology's acquisition of Apexigen, Inc., in August 2023, the Company gained rights to royalties on Beovu and another asset discovered using APXiMAB, Apexigen's proprietary antibody discovery platform.

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

See News Rankings